Mwandishi:
Mhariri:
Imeboreshwa:
ULY CLINIC
ULY CLINIC
28 Julai 2026, 17:34:10
iabetic Insipidus (DI)
Diabetic insipidus (DI) is a disorder of water balance characterized by the inability to concentrate urine, resulting in the excretion of large volumes of dilute urine. It is caused by non-osmotic renal loss of water and may lead to dehydration, hypernatremia, and disturbances in fluid and electrolyte balance if untreated. Diabetes insipidus is distinct from diabetes mellitus, as it is not related to abnormalities in blood glucose metabolism but rather to deficiencies in antidiuretic hormone (ADH) secretion or action.
Pathophysiology
Antidiuretic hormone (ADH), also known as arginine vasopressin (AVP), is synthesized in the hypothalamus and released from the posterior pituitary gland. ADH acts on the renal collecting ducts to promote water reabsorption and maintain body water homeostasis. Diabetes insipidus develops when there is inadequate ADH secretion, impaired renal responsiveness to ADH, or excessive water intake that suppresses ADH secretion.
Classification
Central diabetes insipidus
Caused by complete or partial deficiency of antidiuretic hormone (ADH) secretion from the posterior pituitary gland.
Nephrogenic diabetes insipidus
Caused by end-organ unresponsiveness of the kidneys to ADH despite normal or elevated hormone levels.
Dipsogenic diabetes insipidus
Caused by excessive and inappropriate fluid intake due to a defect in the thirst mechanism, resulting in suppression of ADH secretion.
Risk factors
Head trauma
Pituitary or hypothalamic surgery
Pituitary tumors
Central nervous system infections
Autoimmune disorders affecting the pituitary or hypothalamus
Genetic disorders affecting ADH production or renal response
Chronic kidney disease
Long-term use of lithium or other nephrotoxic drugs
Hypercalcemia
Hypokalemia
Signs and symptoms
Clinical manifestations are primarily related to excessive urinary water loss and compensatory thirst.
Common features include:
Polyuria, especially nocturnal polyuria
Polydipsia
Nocturia
Passage of large volumes of dilute urine
Dehydration
Dry mouth
Fatigue
Volume depletion
Orthostatic hypotension
Hypernatremia in patients unable to replace water losses
Diagnostic criteria
Diagnosis is suggested by the presence of:
Polyuria with urine osmolality <300 mOsm/kg for a given plasma osmolality
Volume depletion and orthostatic hypotension
Plasma sodium concentration that may be normal or elevated
Investigations
Urine osmolality
Plasma osmolality
Serum sodium concentration
Serum electrolytes
Renal function tests
Water deprivation test when diagnosis is uncertain
Desmopressin response test to differentiate central from nephrogenic diabetes insipidus
MRI of the hypothalamic-pituitary region when central diabetes insipidus is suspected
Management
Treatment aims to restore water balance, correct dehydration, treat the underlying cause, and reduce excessive urine output.
Non-pharmacological management
Replace water deficits promptly according to the degree of dehydration.
Ensure adequate free water intake to match urinary losses.
Monitor fluid balance, urine output, serum sodium, and plasma osmolality.
Identify and treat the underlying cause where possible.
Educate patients regarding adequate hydration and recognition of dehydration symptoms.
Pharmacological management
Central diabetes insipidus
Desmopressin is the treatment of choice.
Desmopressin (IV) 2–4 µg/day, divided every 12 hours.
OR
Desmopressin (PO) initial dose 0.05 mg every 12 hours; effective dose range 0.1–1.2 mg/day, divided every 8–12 hours.
OR
Desmopressin (intranasal) 10–40 µg (0.1–0.4 mL) once daily, either as a single dose or divided into two or three doses; the usual dose is 20 µg (0.2 mL) daily in two divided doses.
Nephrogenic diabetes insipidus
Treat the underlying cause whenever possible.
Thiazide diuretics may reduce urine volume.
Bendrofluazide (PO) 5 mg once daily
OR
Hydrochlorothiazide (PO) 12.5–25 mg once daily.
Prognosis
The prognosis depends on the underlying cause and the type of diabetes insipidus. Central diabetes insipidus usually responds well to desmopressin replacement therapy, allowing most patients to achieve good long-term control of symptoms. Nephrogenic diabetes insipidus may be more difficult to manage but can improve with treatment of the underlying cause, appropriate hydration, and thiazide therapy. Early diagnosis and adequate management help prevent recurrent dehydration, hypernatremia, and associated complications.
Imeandikwa:
28 Julai 2026, 17:00:39
Rejea za mada hii:
Ministry of Health, United Republic of Tanzania. Standard Treatment Guidelines and National Essential Medicines List Tanzania Mainland. 2021
Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, editors. Williams Textbook of Endocrinology. 15th Edition. Elsevier; 2024.
Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. 21st Edition. McGraw-Hill Education; 2022.
Fenske WK, Refardt J, Chifu I, et al. European Society of Endocrinology Clinical Practice Guideline on the Diagnosis and Management of Diabetes Insipidus. European Journal of Endocrinology. 2024;190(2):G1–G43.
Disclaimer: The information provided on this platform is for educational and informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Clinical recommendations are primarily based on the Tanzania Standard Treatment Guidelines and National Essential Medicines List (STG & NEMLIT), Seventh Edition, 2021, unless otherwise stated.
